ImmunityBio, Inc. (IBRX) stock analysis
Healthcare · Biotechnology
From the 10-K filed 2026-02-23
How it makes money
Patients with bladder cancer pay for ANKTIVA to boost immune responses.
The company generates revenue by selling its lead biologic, ANKTIVA. Full-year net product revenue reached $113 million, which was a 700% increase year-over-year.
Revenue growth is driven by increasing unit sales and expanding the drug's availability through new regulatory approvals.
What protects it: the moat
Management claims its proprietary technology protects its market position.
It asserts that its Cancer BioShield platform, which uses a proprietary protein to activate immune cells, protects its market position.
What growth costs
It must spend money on clinical trials and expanding its product sales.
To scale, the company must fund the commercialization of its existing products and the development of new ones through clinical trials.
What could damage it
Revenue-sharing agreements could limit the company's ability to operate freely.
A specific agreement known as the RIPA mandates revenue interest payments. These payments and their associated legal rules can restrict how the company manages its business.
About ImmunityBio, Inc.
ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company's platform has generated first-in-human therapeutic agents that are planned to be studied in clinical trials in liquid and solid tumors. Its lead biologic product candidate includes Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors; and 3M-052, a synthetic TLR7/8 agonist and 3M-052 formulations and related technology. The company has collaboration agreements with National Cancer Institute; Serum Institute of India Private Limited; and BeOne Medicines Ltd. It has license agreement with 3M Innovative Properties Company and Access to Advanced Health Institute. ImmunityBio, Inc. is based in San Diego, California.